EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia
It is indicated in patients who have received at least one prior therapy, or in first-line treatment for patients unsuitable for chemo-immunotherapy